RNXT (RenovoRx, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by RNXT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-15 | MARK VOLL | Chief Financial Officer | A | — | — |
| 2026-06-24 | UNA S RYAN | Director | J | — | — |
| 2026-05-21 | MARK VOLL | Chief Financial Officer | Buy | — | — |
| 2026-04-07 | Leesa Gentry | Chief Clinical Officer | A | — | — |
| 2026-04-07 | Shaun Bagai | Chief Executive Officer | A | — | — |
| 2026-04-07 | Ramtin Agah | Chief Medical Officer | A | — | — |
| 2026-04-07 | MARK VOLL | Chief Financial Officer | A | — | — |
| 2026-03-27 | MARK VOLL | Chief Financial Officer | A | — | — |
| 2026-03-24 | MARK VOLL | Chief Financial Officer | Buy | — | — |
| 2026-03-24 | Laurence Marton | Director | Buy | — | — |
| 2026-03-24 | Shaun Bagai | Chief Executive Officer | Buy | — | — |
| 2026-01-22 | Ramtin Agah | Chief Medical Officer | Buy | — | — |
| 2026-01-05 | Ramtin Agah | Chief Medical Officer | Buy | — | — |
| 2026-01-02 | Ramtin Agah | Chief Medical Officer | Buy | — | — |
| 2025-12-22 | Shaun Bagai | Chief Executive Officer | Buy | — | — |
| 2025-12-19 | Shaun Bagai | Chief Executive Officer | Buy | — | — |
| 2025-12-17 | Ramtin Agah | Chief Medical Officer | Buy | — | — |
| 2025-12-08 | Ramtin Agah | Chief Medical Officer | Buy | — | — |
| 2025-11-24 | Ramtin Agah | Chief Medical Officer | Buy | — | — |
| 2025-10-03 | Laurence Marton | Director | A | — | — |
| 2025-10-02 | UNA S RYAN | Director | A | — | — |
| 2025-10-02 | K. Angela Macfarlane | Director | A | — | — |
| 2025-10-02 | Robert J. Spiegel | Director | A | — | — |
| 2025-08-26 | Shaun Bagai | Chief Executive Officer | Buy | — | — |
| 2025-07-03 | Shaun Bagai | Chief Executive Officer | A | — | — |
| 2025-07-03 | Leesa Gentry | Chief Clinical Officer | A | — | — |
| 2025-07-03 | Ron Kocak | VP, Controller and PAO | A | — | — |
| 2025-07-03 | Ramtin Agah | Chief Medical Officer | A | — | — |
| 2025-06-09 | Ramtin Agah | Chief Medical Officer | Buy | — | — |
| 2025-06-06 | Ramtin Agah | Chief Medical Officer | G | — | — |
| 2025-05-06 | Laurence Marton | Director | M | — | — |
| 2025-04-17 | Ramtin Agah | Chief Medical Officer | Buy | — | — |
| 2025-04-16 | Shaun Bagai | Chief Executive Officer | A | — | — |
| 2025-04-16 | Ron Kocak | VP, Controller and PAO | A | — | — |
| 2025-04-16 | Ramtin Agah | Chief Medical Officer | A | — | — |
| 2025-04-16 | Leesa Gentry | Chief Clinical Officer | A | — | — |
| 2025-04-16 | Shaun Bagai | Chief Executive Officer | Buy | — | — |
| 2025-04-14 | Ramtin Agah | Chief Medical Officer | Buy | — | — |
| 2025-04-10 | Ramtin Agah | Chief Medical Officer | Buy | — | — |
| 2025-04-10 | Shaun Bagai | Chief Executive Officer | Buy | — | — |
| 2025-04-10 | Ron Kocak | VP Controller and PAO | Buy | — | — |
| 2025-04-09 | Laurence Marton | Director | Buy | — | — |
| 2025-04-09 | Ramtin Agah | Chief Medical Officer | Buy | — | — |
| 2025-04-08 | Shaun Bagai | Chief Executive Officer | Buy | — | — |
| 2024-10-02 | K. Angela Macfarlane | Director | A | — | — |
| 2024-10-02 | UNA S RYAN | Director | A | — | — |
| 2024-10-02 | Robert J. Spiegel | Director | A | — | — |
| 2024-10-02 | Laurence Marton | Director | A | — | — |
| 2024-03-08 | Leesa Gentry | Chief Clinical Officer | A | — | — |
| 2024-02-12 | Ron Kocak | VP, Controller and PAO | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chief Medical Officer | 1,773,460 | — |
| — | Chief Executive Officer | 364,340 | — |
| — | Chief Financial Officer | 319,580 | — |
| — | Director | 80,959 | — |
| — | Director | 75,884 | — |
| — | Director | 40,983 | — |
| — | Director | 40,983 | — |
| — | VP, Controller and PAO | 12,595 | — |
| — | Chief Operating Officer | 300 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RNXT quote page; the site-wide leaderboard is on the insider transactions hub.